Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 2
1986 1
2007 1
2009 1
2010 1
2011 2
2012 1
2013 1
2014 2
2017 2
2020 2
2022 3
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Reply to Viel.
Recknor C, Hansen SG, Gaylis NB, Tiwary M, Sacha JB, Yang OO. Recknor C, et al. Among authors: gaylis nb. Clin Infect Dis. 2022 Oct 12;75(8):1486-1487. doi: 10.1093/cid/ciac390. Clin Infect Dis. 2022. PMID: 35819204 No abstract available.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators. Fleischmann R, et al. Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16. Lancet. 2017. PMID: 28629665 Clinical Trial.
Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study.
Wiland P, Jeka S, Dokoupilová E, Brandt-Jürgens J, Miranda Limón JM, Cantalejo Moreira M, Cabello RV, Jauch-Lembach J, Thakur A, Haliduola H, Brueckmann I, Gaylis NB. Wiland P, et al. Among authors: gaylis nb. BioDrugs. 2020 Dec;34(6):809-823. doi: 10.1007/s40259-020-00447-6. BioDrugs. 2020. PMID: 33119861 Free PMC article. Clinical Trial.
Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.
Emery P, Mease PJ, Rubbert-Roth A, Curtis JR, Müller-Ladner U, Gaylis NB, Williams S, Reynard M, Tyrrell H. Emery P, et al. Among authors: gaylis nb. Rheumatology (Oxford). 2011 Dec;50(12):2223-32. doi: 10.1093/rheumatology/ker253. Epub 2011 Sep 16. Rheumatology (Oxford). 2011. PMID: 21926153 Free PMC article. Clinical Trial.
21 results